Lima-Gómez V, Somilleda-Ventura SA

Idioma: Español
Referencias bibliográficas: 23
Paginas: 272-277
Archivo PDF: 173.87 Kb.

RESUMEN

Objetivo: Identificar la proporción de ojos que presentan recurrencia del edema macular diabético a los 6 meses de la fotocoagulación focal. Método: Estudio observacional, analítico, transversal y prospectivo, en pacientes con edema macular diabético tratados con fotocoagulación focal. Se identificaron la proporción y los intervalos de confianza del 95% (IC 95%) en los ojos que presentaron recurrencia, y se compararon las medianas de las variables anatómicas y la agudeza visual mediante U de Mann-Whitney. Resultados: Se evaluaron 145 ojos y solo 10 (IC 95%: 2.8-11) presentaron recurrencia del edema macular diabético. Los promedios de grosor del punto central y del campo central fueron mayores en los ojos con recurrencia, pero la diferencia de promedio de cambio entre grupos no fue significativa. Conclusión: La proporción de recurrencia del edema macular 6 meses después de la fotocoagulación focal es menor que la reportada para otros tratamientos de esta enfermedad y menor también que en otros estudios en los que se utilizó fotocoagulación.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2013;19:52-9.

2. Zhang X, Zeng H, Bao S, Wang N, Gillies M. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.

3. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta- analysis. BMJ Open. 2013;3(3). pii: e002269.

4. Federman JL. Retina and vitreous text. St. Louis: Mosby-Year Book; 1994.

5. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254-64.

6. Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco-Suñe C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014;10:100-12.

7. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98.

8. Dhibi HAA, Arevalo JF. Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes. 2013;4:295-302.

9. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761-74.

10. Lee HY, Lee SY, Park JS. Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema. Korean J Ophthalmol. 2009;23:153-8.

11. Shimonagano Y, Doi N, Noda Y, Uemura A, Sakamoto T. Recurrence of diabetic macular edema after intravitreous injection of triamcinolone following vitrectomy. Jpn J Ophthalmol. 2007;5:278-84.

12. Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J (Engl). 2011;124: 352-8.

13. Wykoff CC, Hariprasad SM. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015;46:302-5.

14. Liegl R, Langer J, Seidensticker F, Reznicek L, Haritoglou C, Ulbig MW, et al. Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS One. 2014;9:e113981.

15. Barteselli G, Kozak I, El-Emam S, Chhablani J, Cortes MA, Freeman WR. 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation. Br J Ophthalmol. 2014;98:1036-41.

16. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-54.

17. Takamura Y, Tomomatsu T, Matsumura T, Arimura S, Gozawa M, Takihara Y, et al. The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci. 2014;55:4741-6.

18. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study. Ranibizumab monotherpy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25.

19. Neubauer AS, Langer J, Liegl R, Haritoglou C, Wolf A, Kozak I, et al. Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol. 2013;7:121-8.

20. Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120:1835-42.

21. Mitchell P, Wong TY. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014;157:505-13.

22. Koo NK, Jin HC, Kim YC. Relationship between the morphology of diabetic macular edema and renal dysfunction in diabetes. Korean J Ophthalmol. 2013;27:98-102.

23. Perente I, Alkin Z, Ozkaya A, Dardabounis D, Ogreden TA, Konstantinidis A, et al. Focal laser photocoagulation in non-center involved diabetic macular edema. Med Hypothesis Discov Innov Ophthalmol. 2014;3:9-16.